The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Shaker A. Mousa

Albany College of Pharmacy

The Pharmaceutical Research Institute (PRI)

106 New Scotland Avenue




Name/email consistency: high



  • Albany College of Pharmacy, The Pharmaceutical Research Institute (PRI), 106 New Scotland Avenue, Albany, USA. 2002 - 2008
  • Albany College of Pharmacy, NY 12208-3492, USA. 2002 - 2003


  1. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Mousa, S.A., Bergh, J.J., Dier, E., Rebbaa, A., O'Connor, L.J., Yalcin, M., Aljada, A., Dyskin, E., Davis, F.B., Lin, H.Y., Davis, P.J. Angiogenesis (2008) [Pubmed]
  2. Cell adhesion molecules: potential therapeutic & diagnostic implications. Mousa, S.A. Mol. Biotechnol. (2008) [Pubmed]
  3. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Mousa, S.A. Semin. Thromb. Hemost. (2007) [Pubmed]
  4. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. Mousa, S.A., Zhang, F., Aljada, A., Chaturvedi, S., Takieddin, M., Zhang, H., Chi, L., Castelli, M.C., Friedman, K., Goldberg, M.M., Linhardt, R.J. J. Clin. Pharmacol (2007) [Pubmed]
  5. Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds. Mousa, S.A., O'Connor, L., Rossman, T.G., Block, E. Carcinogenesis (2007) [Pubmed]
  6. Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. Mousa, S.A., Goncharuk, O., Miller, D. Expert. Opin. Biol. Ther (2007) [Pubmed]
  7. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. Mousa, S.A., Ahmad, S. Am. J. Hematol. (2007) [Pubmed]
  8. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography. Mousa, S.A. Blood Coagul. Fibrinolysis (2007) [Pubmed]
  9. From nutraceuticals to pharmaceuticals to nanopharmaceuticals: a case study in angiogenesis modulation during oxidative stress. Mousa, S.A., Bharali, D.J., Armstrong, D. Mol. Biotechnol. (2007) [Pubmed]
  10. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. Mousa, S.A. Int. Angiol (2006) [Pubmed]
  11. Role of current and emerging antithrombotics in thrombosis and cancer. Mousa, S.A. Drugs. Today (2006) [Pubmed]
  12. Synthetic oligosaccharide stimulates and stabilizes angiogenesis: structure-function relationships and potential mechanisms. Mousa, S.A., Feng, X., Xie, J., Du, Y., Hua, Y., He, H., O'Connor, L., Linhardt, R.J. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
  13. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Mousa, S.A., Linhardt, R., Francis, J.L., Amirkhosravi, A. Thromb. Haemost. (2006) [Pubmed]
  14. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Mousa, S.A., Davis, F.B., Mohamed, S., Davis, P.J., Feng, X. Int. Angiol (2006) [Pubmed]
  15. Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138. Mousa, S.A., Mohamed, S. J. Cardiovasc. Pharmacol. (2005) [Pubmed]
  16. Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationship. Mousa, S.A. J. Cell. Biochem. (2005) [Pubmed]
  17. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans. Mousa, S.A., Bozarth, J.M., Seiffert, D., Feuerstein, G.Z. Blood Coagul. Fibrinolysis (2005) [Pubmed]
  18. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist. Mousa, S.A., Mohamed, S., Wexler, E.J., Kerr, J.S. Anticancer Res. (2005) [Pubmed]
  19. Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species. Mousa, S.A. J. Cardiovasc. Pharmacol. (2005) [Pubmed]
  20. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. Mousa, S.A., Johansen, K. Int. Angiol (2005) [Pubmed]
  21. Emerging links between thrombosis, inflammation and cancer: role of heparin. Mousa, S.A. Acta Chir. Belg. (2005) [Pubmed]
  22. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. Mousa, S.A., O'Connor, L.J., Bergh, J.J., Davis, F.B., Scanlan, T.S., Davis, P.J. J. Cardiovasc. Pharmacol. (2005) [Pubmed]
  23. Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin. Mousa, S.A. Int. Angiol (2005) [Pubmed]
  24. Antithrombotics in thrombosis and cancer. Mousa, S.A. Hamostaseologie (2005) [Pubmed]
  25. Anti-thrombotics in thrombosis and cancer. Mousa, S.A. Future. Oncology. (london,. England) (2005) [Pubmed]
  26. Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?. Mousa, S.A., Abdel-Razeq, H.N. Cardiovasc. Drug. Rev (2005) [Pubmed]
  27. Angiogenesis inhibitors: current & future directions. Mousa, S.A., Mousa, A.S. Curr. Pharm. Des. (2004) [Pubmed]
  28. Low-molecular-weight heparin in thrombosis and cancer. Mousa, S.A. Semin. Thromb. Hemost. (2004) [Pubmed]
  29. Low-molecular-weight heparins in thrombosis and cancer: emerging links. Mousa, S.A. Cardiovasc. Drug. Rev (2004) [Pubmed]
  30. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Mousa, S.A., Mohamed, S. Thromb. Haemost. (2004) [Pubmed]
  31. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Mousa, S.A., Mohamed, S. Oncol. Rep. (2004) [Pubmed]
  32. alphav Vitronectin receptors in vascular-mediated disorders. Mousa, S.A. Med. Res. Rev (2003) [Pubmed]
  33. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. Mousa, S.A. Curr. Pharm. Des. (2003) [Pubmed]
  34. Antithrombotics in thrombosis and cancer. Mousa, S.A. Expert. Rev. Cardiovasc. Ther (2003) [Pubmed]
  35. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Mousa, S.A. Curr. Opin. Chem. Biol (2002) [Pubmed]
  36. Antithrombotics and thrombolytics in stroke. Mousa, S.A., Iqbal, O., Fareed, J. Curr. Opin. Investig. Drugs (2002) [Pubmed]
  37. Differential efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet/fibrin-mediated clot dynamics under different conditions using thrombelastography: the critical need for anticoagulant. Mousa, S.A., Forsythe, M.S., Bozarth, J.M. Coron. Artery Dis. (2002) [Pubmed]
  38. Heparin and low molecular weight heparin in thrombosis and beyond. Mousa, S.A. Curr. Opin. Investig. Drugs (2002) [Pubmed]
  39. Vitronectin receptors in vascular disorders. Mousa, S.A. Curr. Opin. Investig. Drugs (2002) [Pubmed]
  40. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Mousa, S.A. Cardiovasc. Drug. Rev (2002) [Pubmed]
WikiGenes - Universities